Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
- Sponsor
- National Cancer Centre, Singapore
- Study ID
- NCT03093831
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Lymphoma, B-Cell, Marginal Zone
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ibrutinib — DRUG560mg administered orally once daily.
Study Details
The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.
Key Dates
- Start date
- Jul 8, 2016
- Status verified
- Oct 2023
- Primary completion
- Jul 17, 2020
- Completion
- Jul 17, 2020
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ibrutinib
Primary Outcome Measure
Overall Response Rates [ Time Frame: From time of first study drug administration until best overall response of CR or PR is achieved, up to 3 years ]